Product
third-generation EGFR-TKI
1 clinical trial
1 indication
Indication
Lung CancerClinical trial
Gumarontinib Combined With Third-generation EGFR-TKI in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Amplification Following EGFR-TKI Treatment Failure.Status: Not yet recruiting, Estimated PCD: 2027-12-12